Diligence memo · auto-generated · as of July 2, 2026
Polarityte, Inc.
Polarityte, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Polarityte, Inc. operates in Biotechnology, based in SALT LAKE CITY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Polarityte, Inc. has raised $24M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2017-09-20.
Most recent recorded round closed around 2022-06-05.
Valuation (modeled)modeled
Provath models Polarityte, Inc. at approximately $69M (range $8.0M–$185M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.41× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era. Issuer reports $5M–$25M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 33 months.
Last raise 4.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 4.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 71% of Biotechnology peers (4293 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.